| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -4.4 | -5.9 |
| Net income | -4.5 | -6.0 |
| EPS (diluted, $ a share) | $-0.15 | $-0.20 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: XBIT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
XBiotech Inc.: key numbers
- Share price
- $1.85Close, Nov 16
- Market cap
- $56.4M
- Shares outstanding
- 30.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from XBiotech Inc.
All →XBiotech Director John Simard Buys $143K of Stock
John Simard, Director, bought 70,000 shares of XBiotech Inc. at $2.05 a share, worth $143K in total on Nov 3, 2026. Shares held after the trade: 4,261,690 (+1.7%).
- Value
- $143K
- Shares
- 70,000
- Price
- $2.05
- Role
- Director
- Holding change
- +1.7%
- Trade date
- Nov 3, 2026
XBiotech Director John Simard Buys $711K of Stock
John Simard, Director, bought 368,524 shares of XBiotech Inc. at $1.93 a share, worth $711K in total on Oct 26, 2026. Shares held after the trade: 4,191,690 (+9.6%).
- Value
- $711K
- Shares
- 368,524
- Price
- $1.93
- Role
- Director
- Holding change
- +9.6%
- Trade date
- Oct 26, 2026
XBiotech Executive Compensation
XBiotech has appointed Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers, effective October 23, 2026. Dr. Shivaswamy will maintain her $750,000 annual salary, while Jan-Paul Simard entered into a new employment agreement with a $150,000 base salary and a one-time grant of 2,000,000 stock options vesting over three years.
- Term
- 3 years